SPC192
Samsetning af empagliflozin og linagliptin eða lyfjafræðilega nothæft salt þar af
Status:
AfskrifuðApplication date:
10.5.2017Application published:
15.6.2017Grant published:
15.5.2018
Max expiry date:
14.11.2031Medicine name:
GlyxambiMedicine for children:
No
Timeline
Today
10.5.2017Application
15.6.2017Publication
15.5.2018Registration
14.11.2031Expires
Marketing license
IS authorization number:
EU/1/16/1146/001-009; EU/1/16/1146/010/018Date:
5.12.2016
Foreign authorization number:
EU/1/16/1146Date:
11.11.2016
Owner
Name:
Boehringer Ingelheim International GmbHAddress:
Binger Strasse 173, Ingelheim am Rhein DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2187879